Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

D. DiNardo, Courtney; Soo Tiong, Ing; Quaglieri, Anna; MacRaild, Sarah; Loghavi, Sanam; C. Brown, Fiona; Thijssen, Rachel; Pomilio, Giovanna; Ivey, Adam; M. Salmon, Jessica; Glytsou, Christina; Fleming, Shaun; Zhang, Q.; Ma, Huaxian; P. Patel, Keyur; M. Kornblau, Steven; Xu, Zhen; Chyn Chua, Chong; Chen, Xufeng; Blombery, Piers; Flensburg, Christoffer; Cummings, Nik; Aifantis, Iannis; M. Kantarjian, Hagop; C.S. Huang, David; W. Roberts, Andrew; J. Majewski, Ian; Konopleva, Marina; H. Wei, Andrew

doi:10.1182/blood.2019003988

Public

Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML

Published in Blood • Jan 14, 2020

Authors:

Courtney D. DiNardo

Ing Soo Tiong

Anna Quaglieri

Abstract

The BCL-2 inhibitor venetoclax combined with hypomethylating agents or low-dose cytarabine represents an important new therapy for older or unfit patients with acute myeloid leukemia (AML). We analyzed 81 patients receiving these venetoclax-based combinations to identify molecular correlates of dura...

Subject

Venetoclax

NPM1

Cytarabine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!